Actinium Pharmaceuticals and Immedica Announce Commercialization Agreement for Iomab-B
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, and Immedica Pharma AB (“Immedica”) today announced entering a license and supply agreement for Iomab-B, an Antibody Radiation Conjugate comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131 that is being developed for targeted conditioning to facilitate bone marrow transplant (BMT) and other cell and gene therapies. A pivotal Phase 3 trial, Study of Iomab-B versus Conventional Care in Elderly, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA), of Iomab-B completed patient enrollment in the third quarter of 2021 with topline data expected in the third quarter of 2022. BMT is the only potentially curative treatment option for patients with active, relapsed or refractory acute myeloid leukemia (AML).
Read moreNews
Impilo’s portfolio company Decon acquires Acekare – a French-based manufacturer and distributor of mobility assistance solutions
The acquisition of Acekare marks an important step in Decon’s strategic ambition to build a leading European niche mobility platform by adding a complementary product company to its existing offering and establishing a direct presence in the French market
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo completes the acquisition of Oticon Medical
We are pleased to announce that Impilo has today completed the acquisition of Oticon Medical from Demant A/S. This marks the first investment in our recently raised Fund II.